Deciphering regulatory principles of proteasome heterogeneity and the degradation landscape in cancer
The project aims to enhance understanding of proteasome activity in cancer through MAPP technology, exploring its role in tumor-immune interactions and potential for improving immunotherapy outcomes.
Projectdetails
Introduction
Proteasome activity is crucial to the removal of defective or obsolete proteins, cell signaling, and antigen presentation. In cancer, proteasomal degradation has been shown to play key roles in tumor growth, antigenicity, and response to immunotherapy. Yet, comprehensive analysis of proteasome subunit composition and the degradation landscape in cancer has not been performed to date, rendering our understanding of inter-patient proteasome heterogeneity and proteasome-dependent mechanisms underlying tumor-immune interactions far from complete.
Methodology
Our novel, unbiased approach, MAPP, for MS Analysis of Proteasome-cleaved Peptides, is ideally suited to examine the missing link between cellular degradation and cancer immunity. We have already demonstrated its utility in identifying degradation events associated with inflammation, proteasome cleavage, substrate alterations, and an anti-inflammatory role of the proteasome subunit PSME4 in lung cancer.
Objectives
We aim to capitalize on our powerful analytical methods, vast experience, and preliminary data to further develop our cutting-edge technology, shedding light on the uncharted area of degradation pathways in cancer. We plan to:
- Characterize both proteasome composition and the degradation landscape across cancer types and develop MAPP further to enable in vivo, tissue-specific, and proteasome-type-specific profiling. We strive to provide a near-complete narrative of proteasome activity and distribution in tumors and their role in shaping tumor-immune interactions.
- Study proteasome-dependent mechanisms underlying tumor immunogenicity and response to immunotherapy at the biochemical, cellular, and physiological levels.
- Exploit inter-patient proteasome heterogeneity for translational opportunities, in particular as an adjunct to current immunotherapies.
Impact
Cancer_Deg will transform our understanding of proteasomal degradation in cancer, with important implications for numerous diseases, precision oncology, and drug discovery.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.978.750 |
Totale projectbegroting | € 1.978.750 |
Tijdlijn
Startdatum | 1-8-2022 |
Einddatum | 31-7-2028 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- WEIZMANN INSTITUTE OF SCIENCEpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Protease Profiling and Triggered Drug Delivery for Personalized Cancer TherapyPROTECT aims to develop a novel platform using Liposomal Activity-Based Sensors for sensitive protease profiling to enhance cancer diagnostics and personalized drug delivery. | ERC Consolid... | € 1.842.642 | 2022 | Details |
Proteomic Analysis of Cell communication in TumorsThis project aims to analyze cancer proteome dynamics at single-cell resolution to understand tumor heterogeneity and improve personalized treatment for resistant metastatic cells. | ERC Consolid... | € 2.000.000 | 2022 | Details |
An integrative genetic approach for the exploration of melanoma immunological interactionsThis project aims to enhance cancer vaccine efficacy by systematically analyzing the immunopeptidome in melanoma to identify actionable neopeptides and their impact on immune responses. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and DiagnosisEpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors. | ERC Starting... | € 1.500.000 | 2024 | Details |
Targeting the Polycomb Machinery in BAP1-related PathologiesThe T-BAP project aims to develop targeted compounds against PRC1.3/5 to restore normal H2Aub1 levels and create therapeutic strategies for cancers linked to BAP1 mutations. | ERC Proof of... | € 150.000 | 2024 | Details |
Protease Profiling and Triggered Drug Delivery for Personalized Cancer Therapy
PROTECT aims to develop a novel platform using Liposomal Activity-Based Sensors for sensitive protease profiling to enhance cancer diagnostics and personalized drug delivery.
Proteomic Analysis of Cell communication in Tumors
This project aims to analyze cancer proteome dynamics at single-cell resolution to understand tumor heterogeneity and improve personalized treatment for resistant metastatic cells.
An integrative genetic approach for the exploration of melanoma immunological interactions
This project aims to enhance cancer vaccine efficacy by systematically analyzing the immunopeptidome in melanoma to identify actionable neopeptides and their impact on immune responses.
Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and Diagnosis
EpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors.
Targeting the Polycomb Machinery in BAP1-related Pathologies
The T-BAP project aims to develop targeted compounds against PRC1.3/5 to restore normal H2Aub1 levels and create therapeutic strategies for cancers linked to BAP1 mutations.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
The ProM platform: New ways to drug the undruggablePROSION's ProM-platform aims to unlock and target the undruggable 85% of the human proteome, developing new therapies for hard-to-treat diseases like cancer. | EIC Accelerator | € 2.461.375 | 2022 | Details |
A multiplexed biomimetic imaging platform for assessing single cell plasticity (Plastomics) and scoring of tumour malignancyThe PLAST_CELL project aims to develop a microfluidics-based imaging platform to quantify cancer cell plasticity, enhancing diagnosis and treatment of metastasis and therapy resistance. | EIC Pathfinder | € 2.982.792 | 2022 | Details |
The ProM platform: New ways to drug the undruggable
PROSION's ProM-platform aims to unlock and target the undruggable 85% of the human proteome, developing new therapies for hard-to-treat diseases like cancer.
A multiplexed biomimetic imaging platform for assessing single cell plasticity (Plastomics) and scoring of tumour malignancy
The PLAST_CELL project aims to develop a microfluidics-based imaging platform to quantify cancer cell plasticity, enhancing diagnosis and treatment of metastasis and therapy resistance.